Cost-effectiveness of check of medication appropriateness: methodological approach

2022 ◽  
Author(s):  
Erinn D’hulster ◽  
Charlotte Quintens ◽  
Raf Bisschops ◽  
Rik Willems ◽  
Willy E. Peetermans ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Methodological Approach ◽  
Medication Appropriateness

Classification of evidence in decision-analytic models of cost-effectiveness: A content analysis of published reports

2010 ◽  
Vol 26 (4) ◽  
pp. 458-462 ◽  
Author(s):  
Suzy Paisley
Keyword(s):  
Content Analysis ◽  
Cost Effectiveness ◽  
Methodological Approach ◽  
Model Development ◽  
Three Dimensions ◽  
Model Parameters ◽  
Modeling Framework ◽  
Diverse Range ◽  
Analytic Models

Objectives: The aim of this study was to assess systematically the scope of evidence and purposes for which evidence is used in decision-analytic models of cost-effectiveness and to assess the implications for search methods.Methods: A content analysis of published reports of models was undertaken. Details of cited sources were extracted and categorized according to three dimensions; type of information provided by the evidence, type of source from which the evidence was drawn and type of modeling activity supported by the evidence. The analysis was used to generate a classification of evidence. Relationships within and between the categories within the classification were sought and the implications for searching considered.Results: The classification generated fourteen types of information, seven types of sources of evidence and five modeling activities supported by evidence. A broad range of evidence was identified drawn from a diverse range of sources including both research-based and non–research-based sources. The use of evidence was not restricted to the population of model parameters but was used to inform the development of the modeling framework and to justify the analytical and methodological approach.Conclusions: Decision-analytic models use evidence to support all aspects of model development. The classification of evidence defines in depth the role of evidence in modeling. It can be used to inform the systematic identification of evidence.

scholarly journals Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICE

2021 ◽  
Author(s):  
Melanie Y. Bertram ◽  
Jeremy A. Lauer ◽  
Karin Stenberg ◽  
Tessa Tan Torres Edejer
Keyword(s):  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Health System ◽  
Priority Setting ◽  
Methodological Approach ◽  
Health Gain ◽  
Cost Effectiveness Analysis ◽  
Added Value ◽  
World Health ◽  
Effectiveness Analysis

The World Health Organization’s (WHO’s) Choosing Interventions that are Cost-Effective (CHOICE) programme has been a global leader in the field of economic evaluation, specifically cost-effectiveness analysis for almost 20 years. WHO-CHOICE takes a "generalized" approach to cost-effectiveness analysis that can be seen as a quantitative assessment of current and future efficiency within a health system. This supports priority setting processes, ensuring that health stewards know how to spend resources in order to achieve the highest health gain as one consideration in strategic planning. This approach is unique in the global health landscape. This paper provides an overview of the methodological approach, updates to analytic framework over the past 10 years, and the added value of the WHO-CHOICE approach in supporting decision makers as they aim to use limited health resources to achieve the Sustainable Development Goals (SDGs) by 2030.

An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine

2016 ◽  
Vol 20 (5) ◽  
pp. 274-282 ◽  
Author(s):  
Vasilios Fragoulakis ◽  
Christina Mitropoulou ◽  
Ron H. van Schaik ◽  
Nikolaos Maniadakis ◽  
George P. Patrinos
Keyword(s):  
Decision Making ◽  
Cost Effectiveness ◽  
Methodological Approach ◽  
Genomic Medicine ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

A New Methodological Approach for Cost-Effectiveness Analysis in Genomic Medicine

2015 ◽  
pp. 131-147
Author(s):  
Vasilios Fragoulakis ◽  
Christina Mitropoulou ◽  
Marc S. Williams ◽  
George P. Patrinos
Keyword(s):  
Cost Effectiveness ◽  
Methodological Approach ◽  
Genomic Medicine ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Introduction to the Special Issue on "The World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update"

2021 ◽  
Author(s):  
Melanie Y. Bertram ◽  
Tessa Tan Torres Edejer
Keyword(s):  
Decision Making ◽  
Cost Effectiveness ◽  
World Health Organization ◽  
Methodological Approach ◽  
Health Benefit ◽  
Cost Effective ◽  
World Health ◽  
Health Coverage ◽  
Health Organization ◽  
Over Time

The WHO-CHOICE (World Health Organization CHOosing Interventions that are Cost-Effective) approach is unique in the global health landscape, as it takes a "generalized" approach to cost-effectiveness analysis (CEA) that can be seen as a quantitative assessment of current and future efficiency within a health system. CEA is a critical contribution to the process of priority setting and decision-making in healthcare, contributing to deliberative dialogue processes to select services to be funded. WHO-CHOICE provides regional level estimates of cost-effectiveness, along with tools to support country level analyses. This series provides an update to the methodological approach used in WHO-CHOICE and presents updated cost-effectiveness estimates for 479 interventions. Five papers are presented, the first focusing on methodological updates, followed by three results papers on maternal, newborn and child health; HIV, tuberculosis and malaria; and non-communicable diseases and mental health. The final paper presents a set of example universal health coverage (UHC) benefit packages selected through only a value for money lens, showing that all disease areas have interventions which can fall on the efficiency frontier. Critical for all countries is institutionalizing decision-making processes. A UHC benefit package should not be static, as the countries needs and ability to pay change over time. Decisions will need to be continually revised and new interventions added to health benefit packages. This is a vital component of progressive realization, as the package is expanded over time. Developing an institutionalized process ensures this can be done consistently, fairly, and transparently, to ensure an equitable path to UHC.

scholarly journals The effectiveness of an innovation ecosystem formation as territory strategic development element

Upravlenie ◽  
2020 ◽  
Vol 7 (4) ◽  
pp. 44-53
Author(s):  
I. V. Korchagina ◽  
O. V. Sychjova-Peredero
Keyword(s):  
Cost Effectiveness ◽  
Methodological Approach ◽  
Economic Cost ◽  
Long Term Effects ◽  
Economic Management ◽  
Innovation Ecosystem ◽  
Strategic Development ◽  
Additional Costs ◽  
Regional Product ◽  
The Cost

The problem of assessing and justifying the cost-effectiveness of creating various elements of an innovation ecosystem of territories, in particular, regions has been analyzed in the article. Most of the constituent entities of the Russian Federation are working on the formation of innovative ecosystems in the context of strategic economic management. However, this raises the issue of budget and economic cost-effectiveness. The purpose of the article is to develop a methodological approach and the main directions of determining the effectiveness of the formation of innovative ecosystems.It has been shown, that it is incorrect to evaluate efficiency only by the direct budget effect. Based on expert interviews the main effects of the development of the region’s innovation ecosystem have been identified and classified. It has been allowed us to clarify specific areas of the influence of the innovation ecosystem on a number of economic indicators, including the gross regional product. The formulas for calculating the most important effects of the development of innovative ecosystems in terms of value have been proposed. The influence of innovation ecosystems on the achievement of public goals of socio-economic development of territories has been noted. Based on data on the development of an innovation ecosystem with a core in the form of a regional support university and the implementation of student entrepreneurial projects, key effects arising from costs from various sources have been identified.It has been shown, that additional costs for the development of innovative ecosystems can be fully justified, provided that a full-fledged funnel of projects is implemented. Attention has been paid to the problem of more complete and accurate assessments of the long-term effects of the development of an innovation ecosystem for spatial significance, migration attractiveness, and the development of human capital of the territory. Conclusions about the significant impact of costs on the formation of an innovation ecosystem on the development of the territory (both existing and potential) have been made.

scholarly journals Methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: The SOHO study

2006 ◽  
Vol 22 (4) ◽  
pp. 460-468 ◽  
Author(s):  
Frank Windmeijer ◽  
Stathis Kontodimas ◽  
Martin Knapp ◽  
Jacqueline Brown ◽  
Josep Maria Haro
Keyword(s):  
Cost Effectiveness ◽  
Incremental Cost ◽  
Methodological Approach ◽  
Cost Effective ◽  
Multivariate Regression Analysis ◽  
New Treatment ◽  
Using Data ◽  
Epoch Analysis ◽  
Mean Function ◽  
The Cost

Objectives: The objective of this study was to develop a method to allocate treatment effects when patients switch medication frequently in longitudinal observational studies and apply the approach to assess the cost-effectiveness of treatments in the Schizophrenia Outpatient Health Outcomes (SOHO) study.Methods: Data were collected on patients at entry to the SOHO study at 3, 6, and 12 months. The 12-month follow-up period was considered as three epochs: 0–3 months, 3–6 months, and 6–12 months. Patients who switched treatment at 3 months had their new treatment considered as a new baseline observation, as these two 3-month observations provide two sets of information on the cost-effectiveness of a drug in the first 3 months after initiation. Multivariate regression analysis was used to adjust for baseline covariates. The model allowed for flexible functional forms, and the cost data were modeled using an exponential mean function. Bootstrapping assessed the uncertainty of the estimated parameters and incremental cost-effectiveness analysis decision rule.Results and Conclusions: We show the feasibility of the epoch analysis approach using data from the SOHO study comparing two antipsychotics. Estimates for the incremental cost and effectiveness per epoch over the full 12-month period are presented. Using the estimates of 200 bootstrap samples, we demonstrate how one drug is cost-effective compared with another.

Sign in / Sign up

Export Citation Format

Share Document